29 May 2026
29 May 2026
The clearance enables ABILITY Neurotech to move beyond intra-operative testing to long-term clinical investigation involving human participants.
The trial will enrol 30 participants diagnosed with IgAN.
Under the agreement, VECOL will act as the primary implementing partner while SK bioscience contributes technology transfer and manufacturing support.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
